RAPT - RAPT Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
24.73
-0.40 (-1.59%)
At close: 4:00PM EST

24.75 +0.02 (0.08%)
After hours: 5:26PM EST

Stock chart is not supported by your current browser
Previous Close25.13
Open25.89
Bid24.75 x 900
Ask28.50 x 800
Day's Range24.26 - 26.24
52 Week Range11.85 - 42.00
Volume60,458
Avg. Volume105,996
Market Cap526M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    RAPT Therapeutics Appoints Mary Ann Gray, Ph.D., to Board of Directors

    RAPT Therapeutics, Inc. (RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Mary Ann Gray, Ph.D., President of Gray Strategic Advisors, LLC, has joined its Board of Directors. “We are pleased to welcome Mary Ann to our Board, as she brings a wealth of scientific and financial expertise from her time investing in and covering biotech companies, as well as broad leadership experience guiding companies as they develop key therapeutics with a wide range of pharmacological applications,” said Brian Wong, M.D., Ph.D., President and CEO of RAPT Therapeutics.

  • GlobeNewswire

    RAPT Therapeutics Appoints Rodney Young as Chief Financial Officer

    RAPT Therapeutics, Inc. (RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the appointment of Rodney Young as chief financial officer effective December 2, 2019. “As a newly public company, we are thrilled to welcome Rodney to RAPT,” said Brian Wong, M.D., Ph.D., president and CEO of RAPT Therapeutics. Mr. Young brings more than 30 years of executive management and corporate finance experience.

  • GlobeNewswire

    RAPT Therapeutics and Hanmi Pharmaceutical Announce Collaboration to Develop and Commercialize FLX475 in Asia

    RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, and Hanmi Pharmaceutical Co., LTD today announced a license and collaboration agreement for FLX475 in Asia. FLX475 is an oral, small molecule CCR4 antagonist in development for the treatment of multiple cancers.

  • Business Wire

    RAPT Therapeutics Announces Pricing of Initial Public Offering

    RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the pricing of its initial public offering of 3,000,000 shares of common stock at a public offering price of $12.00 per share. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 450,000 shares of common stock at the initial public offering price, less the underwriting discount. The shares are expected to begin trading on the Nasdaq Global Market on October 31, 2019, under the ticker symbol “RAPT.” The offering is expected to close on November 4, 2019, subject to the satisfaction of customary closing conditions.